medigraphic.com
ISSN 0016-3813 (Impreso)

2014, Número 4

<< Anterior Siguiente >>

Gac Med Mex 2014; 150 (4)


La metformina incrementa la concentración sérica de adiponectina de alto peso molecular (adiponectina-HMW) en obesos no diabéticos

García GJA, Lara PE, Álvarez HE, Ocharán HME, Gutiérrez IG, Melendro LEI, Amancio CO, Sánchez PV, Hernández RJ, López AJC

Idioma: Español
Referencias bibliográficas: 86
Paginas: 324-333
Archivo PDF: 108.52 Kb.


RESUMEN

Introducción: La obesidad se asocia a un estado de inflamación sistémica crónica de baja intensidad. Objetivo: Evaluar la eficacia de dos dosis diferentes de metformina comparadas con placebo para incrementar los niveles séricos de adiponectina- HMW. Material y métodos: Se desarrolló un diseño experimental con entrecruzamiento farmacológico completo y balanceado, con la participación de 28 mujeres y 8 hombres adultos obesos no diabéticos. Se les asignaron las secuencias de los tratamientos de forma aleatoria: placebo, metformina 500 mg y metformina 850 mg, 2/día, durante una semana, con una semana de lavado entre los tratamientos. Al final de cada tratamiento se midió la adiponectina-HMW en sangre (0 y 120 min). Se realizó un contraste con análisis de la varianza (ANOVA), el post hoc con prueba de Bonferroni y, además, un cálculo del tamaño del efecto de los tratamientos. Resultados: Se midieron las diferencias de concentraciones de adiponectina-HMW (t0’, t120’) para cada tratamiento mediante ANOVA, obteniendo valores de p = 0.03 y 0.002, respectivamente. El análisis post hoc reportó diferencias favorables al tratamiento con metformina 850 mg (p = 0.025). Los tamaños del efecto en los momentos t0’ y t120’ para metformina 500 mg fueron del 34 y el 35%, y para metformina 850 mg, del 65 y el 84%, respectivamente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Forsythe LK, Wallace JM, Livingstone MB. Obesity and inflammation: the effects of weight loss. Nutr Res Rev. 2008;21(2):117-33.

  2. Zhang M, Zhao X, Li M, et al. Abnormal adipokines associated with various types of obesity in Chinese children and adolescents. Biomed Environ Sci. 2011;24(1):12-21.

  3. Cheng KH, Chu CS, Lee KT, et al. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes. 2008;32(2):268-74.

  4. Rocha VZ, Libby P. Obesity, inflammation and atherosclerosis. Nature Reviews. 2009;6(6):399-409.

  5. Rocha VZ, Folco EJ. Inflammatory concepts of obesity. Int J Inflam. 2011;2011:529061.

  6. Gregor MF, GS Hotamisligil. Inflammatory mechanisms in obesity. Ann Rev Immunol. 2011;29:415-45.

  7. Cinti S. Between brown and white: novel aspects of adipocyte differentiation. Ann Med. 2011;43(2):104-15.

  8. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85-97.

  9. Suganami T, Ogawa Y. Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol. 2010;88(1):33-9.

  10. Sell H, Eckel J. Adipose tissue inflammation: novel insight into de role of macrophages and lymphocytes. Curr Opin Clin Nutr Metab Care. 2010;13(4):366-70.

  11. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010;314:1-16.

  12. Ohmura K, Ishimori N, Ohmura Y, et al. Natural killer T cells are involved in adipose tissues inflammation and glucose intolerance in diet-induced obese mice. Arterioscler Thromb Vasc Biol. 2010;30(2):193-9.

  13. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-7.

  14. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel L, Ferrante Jr W. Obesity is associated with macrophage accumulation in adipose issue. J Clin Invest. 2003;112(12):1796-808.

  15. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesión molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473-6.

  16. Villarreal-Molina MT, Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective affects. Biochimie. 2010;94(10):2143-9.

  17. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: Regulation of its production and its role in human diseases. Hormones. 2012;11(1):8-20.

  18. Matsumoto Y, Toyomasu K, Uchimura N, Ishitake T. Low-molecularweight adiponectin is more closely associated with episodes of asthma than high-molecular-weight adiponectin. Endocr J. 2013;60(1):119-25.

  19. Baessler A, Schlossbauer S, Stark K, et al. Adiponectin multimeric forms but not total adiponectin levels are associated with myocardial infarction in non-diabetic men. J Atheroscler Thromb. 2011;18(7):616-27.

  20. El-Menyar A, Rizk N, Al Nabti AD, et al. Total and high molecular weight adiponectin in patients with coronary artery disease. J Cardiovasc Med. 2009;10:310-5.

  21. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/ adiponectin. Proc Natl Acad Sci USA. 2004;101:10308-13.

  22. Yamauchi T, Kamon J, Yto Y, et al. Cloning of adiponectin receptors that mediated antidiabetic metabolic effects. Nature. 2003;423(6941):762-9.

  23. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest. 2010;120:4342-52.

  24. Li H, Xiao Y, Liu H, et al. Hypoadiponectinemia predicts impaired endothelium- independent vasodilation in newly diagnosed type 2 diabetic patients: an 8-year prospective study. Chin Med J. 2011;124(22):3607-12.

  25. Ouedraogo R, Gong Y, Berzins B, et al. Adiponectin deficiency increases leucocyte-endothelium interactions via upregulation of endothelial cell adhesión molecules in vivo. J Clin Invest. 2007;117(6):1718-26.

  26. Xu A, Vanhoutte PM. Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol. 2012;302(6):H1231-40.

  27. Rienstra M, Sun JX, Lubitz SA, et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J. 2012;163(1):119-24.

  28. Takemura Y, Walsh K, Ouchi N. Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler Rep. 2007;9:238-43.

  29. Tamura T, Furukawa Y, Taniquchi R, et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J. 2007;71:623-30.

  30. Gulcelik MA, Colakoglu K, Dincer H, Dogan L, Yenidogan E, Gulcelik NE. Associations between Adiponectin and Two Different Cancers: Breast and Colon. Asian Pac J Cancer Prev. 2012;13(1):395-8.

  31. Saxena A, Chumanevich A, Fletcher E, et al. Adiponectin deficiency: Role in chronic inflammation induced colon cancer. Biochim Biophys Acta. 2012;1822(4):527-36.

  32. Seker M, Bilici A, Guler DO, et al. Tissue and serum adiponectin levels in patients with gastric cancer: are there any correlations between adiponectin levels and histopathological variables? Hepatogastroenterology. 2011;58(110-111):1841-6.

  33. Lu JP, Hou ZF, Duivenvoorden WC, Whelan K, Honig A, Pinthus JH. Adiponectin inhibits oxidative stress in human prostate carcinoma cells. Prostate Cancer Prostatic Dis. 2012;15(1):28-35.

  34. Garruti G, Depalo R, Vita MG, et al. Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. Reprod Biomed Online. 2009;19(4):552-63.

  35. Hernández VM, Zárate A, Galván RE. Concentración de la adiponectina en perimenopáusicas. Ginecol Obstet Mex. 2008;76(8):450-3.

  36. Reyna-Villasmil E, Mejia-Montilla J, Reyna-Villasmil N, Torres-Cepeda D, Peña-Paredes E. Adiponectina plasmática en preeclampsia y eclampsia. Rev Chil Obstet Ginecol. 2008;73(5):381-8.

  37. Yamamoto S, Watabe K, Araki H, et al. Protective role of adiponectin against ethanol-induced gastric injury in mice. Am J Physiol Gastrointest Liver Physiol. 2012;302(8):G773-80.

  38. Hirata A, Kishida K, Nakatsuji H, et al. High prevalence of gastroesophageal reflux symptoms in type 2 diabetics with hypoadiponectinemia and metabolic syndrome. Nutr Metab. 2012;9(1):4.

  39. Kato M, Watabe K, Hamasaki T, et al. Association of low serum adiponectin levels with erosive esophagitis in men: an analysis of 2405 subjects undergoing physical check-ups. J Gastroenterol. 2011;46(12):1361-7.

  40. Parola M, Marra F. Adipokines and redox signaling: impacto of fatty liver disease. Antioxid Redox Signal. 2011;15(2):461-83.

  41. Yuksel H, Sogut A, Yilmaz O, Onur E, Dinc G. Role of adipokines and hormones of obesity in childhood asthma. Allergy Asthma Immunol Res. 2012;4(2):98-103.

  42. Simpson NS, Banks S, Arroyo S, Dinges DF. Effects of sleep restriction on adiponectin levels in healthy men and women. Physiol Behav. 2010;101(5):693-8.

  43. Nagashima T, Okuba-Fornbacher H, Aoki Y, et al. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis. J Rheumatol. 2008;35:936-8.

  44. Senolt L, Pavelka K, Housa D, Haluzik K. Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine. 2006;35:247-52.

  45. Une K, Takei YA, Tomita N, et al. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer’s disease. Eur J Neurol. 2011;18(7):1006-9.

  46. van Himbergen TM, Beiser AS, Ai M, et al. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease. Results from Framingham Heart Study. Arch Neurol. 2012;69(5):594-600.

  47. Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes, and Alzheimer’s disease. J Alzheimers Dis. 2009;16(4):693-704.

  48. Liu M, Liu F. Up-and down-regulation of adiponectin expression and multimerization: mechanisms and therapeutic implication. Biochimie. 2012;94(10):2126-30.

  49. Golay A. Metformin and body weight. Int J Obes (Lond). 2008;32(1):61-72.

  50. Bastarrachea RA, Montero JC, Saavedra-Guajardo V, Cerda-Flores R, Machado-Domínguez A, Comuzie AG. Objetivos moleculares para diseñar nuevos fármacos para el tratamiento de la diabetes tipo 2 y la obesidad. Rev Med Chile. 2008;136:107-17.

  51. Andújar-Plata P, Pi-Sunyer X, Laferrère B. Metformin effects revisited. Diabetes Res Clin Pract. 2012;95(1):1-9.

  52. Zhang L, He H, Balschi JA. Metformin and phenformin activate AMPactivated protein kinase in the heart by increasing cytosolic AMP concentration. Am J Physiol Heart Circ Physiol. 2007;293:457-66.

  53. Wong AF, Howie J, Petrie JR, Lang CC. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clinical Science. 2009;116:607-20.

  54. Boyle JG, Salt IP, McKay GA. Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target. Diabet Med. 2010;27:1097-106.

  55. Ewart MA, Kennedy S. AMPK and vasculoprotection. Pharmacol Ther. 2011;131(2):242-53.

  56. Stephenne X, Foretz M, Taleux N, et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia. 2011;54(12):3101-10.

  57. Singh S, Akhtar N, Ahmad J. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of Metformin treatment in a casecontrol study. Diabetes Metab Syndr. 2012;6(4):207-11.

  58. Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovasc Diabetol. 2012;11:61.

  59. Klempfner R, Leor J, Tenenbaum A, Fisman EZ, Goldenberg I. Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. Cardiovasc Diabetol. 2012;11:60.

  60. Zulian A, Cancello R, Girola A, et al. In vitro and in vivo effects of metformin on human adipose tissue adiponectin. Obes Facts. 2011;4(1):27-33.

  61. Perez A, Jacks R, Arora V, Spanheimer R. Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. J Clin Hypertens. 2010;12(12):973-82.

  62. Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformina monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2011;119(2):63-8.

  63. Trolle B, Lauszus FF, Frystyk J, Flyvbjerg A. Adiponectin levels in women with polycystic ovary syndrome: impact of metformina treatment in a randomized controlled study. Fertil Steril. 2010;94(6):2234-8.

  64. Garinis GA, Fruci B, Mazza A, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes. 2010;34(8):1255-64.

  65. Phillips SA, Kung J, Ciaraldi TP, et al. Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab. 2009;297(3):E767-73.

  66. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res. 2008;1(5):369-75.

  67. Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, Szymczak J, Bednarek- Tupikowska G, Demissie M. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol. 2008;24(7):378-84.

  68. Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate- activated protein kinase. Hepatology. 2008;47(2):677-85.

  69. Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol. 2006;65(6):722-8.

  70. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, México: Instituto Nacional de Salud Pública; 2012.

  71. Hevener AL, Febbraio MA; Stock Conference Working Group. The 2009 stock conference report: inflammation, obesity and metabolic disease. Obes Rev. 2010;11(9):635-44.

  72. García-García E, De la Llata-Romero M, Kaufer-Horwitz M, et al. Obesity and metabolic syndrome. A challenge for the Mexican Institutes of Health. Rev Invest Clin. 2009;61(4):337-46.

  73. Cordova-Villalobos JA, Barriguete-Meléndez JA, Lara-Esqueda A, et al. Chronic non-communicable diseases in Mexico: epidemiologic synopsis and integral prevention. Salud Publica Mex. 2008;50(5):419-27.

  74. Dulloo AG, Montani JP. Body composition, inflammation and thermogenesis in pathways to obesity and the metabolic syndrome: an overview. Obes Rev. 2012;13 Suppl 2:1-5.

  75. Yoon YE, Rivera JJ, Kwon DA, et al. National Cholesterol Education Panel III guidelines performance role in preventing myocardial infarction in a large cohort without a history of coronary artery disease: Korea Acute Myocardial Infarction Registry study. Prev Cardiol. 2009;12(2):109-13.

  76. Vinluan CM, Zreikat HH, Levy JR, Cheabg KI. Comparison of different metabolic syndrome definitions and risks of incident cardiovascular events in the elderly. Metabolism. 2012;61(3):302-9.

  77. Fernández-Bergés D, Félix-Redondo FJ, Lozano L, et al. Prevalencia de SM según las nuevas recomendaciones de la OMS. Estudio Hermex. Gac Sanit. 2011;25(6):519-24.

  78. Fernald DH, Coombs L, DeAlleaume L, West D, Parnes B. An assessment of the Hawthorne effect in practice-based research. J Am Board Fam Med. 2012;25(1):83-6.

  79. Shetty S, Kusminski AM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci. 2009;30(5):234-9.

  80. Ahonen T, Vanhala M, Kautiainen H, Kumpusalo E, Saltevo J. Sex differences in the association of adiponectin and low-grade inflammation with changes in the body mass index from youth to middle age. Gend Med. 2012;9(1):1-8.

  81. Phillips SA, Ciaraldi TP, Kong AP, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003;52(3):667-74.

  82. De Jager J, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2005;257(1):100-9.

  83. Fritz CO, Morris PE, Richler JJ. Effect size estimates: current use, calculations and interpretation. J Exp Psychol Gen. 2012;141(1):2-18.

  84. Levri KM, Slaymaker E, Last A, et al. Metformin as treatment for overweight and obese adults: a systematic review. Ann Fam Med. 2005;3:457-61.

  85. Bouza C, López-Cuadrado T, Gutierrez-Torres LF, Amate J. Efficacy and safety of metformin for treatment overweight and obesity in adolescents: an updated systematic review and meta-analysis. Obes Facts. 2012;5(5):753-65.

  86. Berstein LM. Metformin in obesity, cancer and aging: addressing controversies. Aging. 2012;4(5):320-9.




2020     |     www.medigraphic.com